GlassScriptPhysician profile
Samuel K Evans
NPI 1508029356
$2,050.13
in general payments reported to CMS, 2019-2025
28 companies · $390 in 2025
The $390 reported for 2025 was more than what a typical Critical Care Medicine (Internal Medicine) provider received nationally (typical 2025 total: $189).
See the full distribution for Critical Care Medicine (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14.90 · 2022: $513 · 2023: $568 · 2024: $565 · 2025: $390.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,522.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,522.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $537.21 | 2022-2025 | Airsupra, Breztri, Fasenra |
| Olympus Corporation of The Americas | $262.90 | 2022 | |
| Glaxosmithkline, LLC. | $215.23 | 2022-2025 | Nucala, Trelegy Ellipta, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $139.89 | 2019-2024 | Ofev, Spiriva Respimat, Stiolto Respimat |
| Daiichi Sankyo INC. | $104.06 | 2022 | |
| Novo Nordisk INC | $71.43 | 2022-2024 | Ozempic, Rybelsus |
| Harmony Biosciences LLC | $71.37 | 2023-2024 | Wakix |
| Otsuka America Pharmaceutical, INC. | $58.66 | 2022-2023 | Abilify Mycite |
| Pfizer INC. | $56.82 | 2022-2023 | |
| E.R. Squibb & Sons, L.L.C. | $56.65 | 2024 | Eliquis |
| Genzyme Corporation | $50.32 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $49.31 | 2025 | Dupixent |
| Lilly USA, LLC | $46.32 | 2023 | Mounjaro |
| Exact Sciences Corporation | $40.41 | 2023 | Cologuard Collection Kit |
| Grifols USA, LLC | $39.19 | 2023-2024 | Prolastin-C Liquid |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $25.72 | 2022 | |
| Abbvie INC. | $25.19 | 2024 | |
| Dexcom, INC. | $23.38 | 2023 | Dexcom G6 Transmitter |
| Medtronic, INC. | $20.74 | 2023 | Venaseal |
| Verona Pharma, INC. | $20.60 | 2025 | Ohtuvayre |
| Seqirus USA INC | $19.82 | 2023 | Flucelvax Quadrivalent, Fluad Quadrivalent |
| Sanofi-Aventis U.S. LLC | $18.50 | 2025 | |
| Philips North America LLC | $17.41 | 2025 | Vest Therapy Und |
| Mylan Specialty L.P. | $17.40 | 2024 | Yupelri |
| Phathom Pharmaceuticals, INC. | $16.87 | 2025 | Voquezna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.14 | 2023 | Trulance, Xifaxan |
| Bayer Healthcare Pharmaceuticals INC. | $15.02 | 2023 | |
| Xeris Pharmaceuticals, INC. | $13.57 | 2025 | Gvoke Hypopen |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samuel Evans listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.